title: Lanthanum carbonate reduces urine phosphorus excretion: evidence of high-capacity phosphate binding.
abstract: The effectiveness of phosphate binders can be assessed by evaluating urinary phosphorus excretion in healthy volunteers, which indicates the ability of the phosphate binder to reduce gastrointestinal phosphate absorption. Healthy volunteers were enrolled into one of five separate randomized trials; four were open label and one double blind. Following a screening period of ≤28 days, participants received differing tablets containing lanthanum carbonate [LC, 3000 mg/day of elemental lanthanum (in one study other doses were also used)]. Participants received a standardized phosphate diet and remained in the relevant study center throughout the duration of each treatment period. The end point in all studies was the reduction in urinary phosphorus excretion. Reductions in mean 24-h urinary phosphorus excretion in volunteers receiving a lanthanum dose of 3000 mg/day were between 236 and 468 mg/day over the five separate studies. These data in healthy volunteers can be used to estimate the amount of reduction of dietary phosphate absorption by LC. The reduction in 24-h urinary phosphorus excretion per tablet was compared with published data on other phosphate binders. Although there are limitations, evidence suggests that LC is a very effective phosphate binder in terms of binding per tablet.
authors.affiliation: Shire Pharmaceuticals Group Plc, Basingstoke, UK.
authors.forename: Michael
authors.initials: M
authors.lastname: Pennick
authors.forename: Lynne
authors.initials: L
authors.lastname: Poole
authors.forename: Kerry
authors.initials: K
authors.lastname: Dennis
authors.forename: Michael
authors.initials: M
authors.lastname: Smyth
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D054559:Hyperphosphatemia / Q000139:chemically induced / Q000652:urine; D007676:Kidney Failure, Chronic / Q000178:diet therapy / Q000652:urine; D007811:Lanthanum / Q000008:administration & dosage*; D008297:Male; D010758:Phosphorus / Q000652:urine*; D017553:Phosphorus Compounds / Q000378:metabolism; D016226:Phosphorus, Dietary / Q000493:pharmacokinetics; D012016:Reference Values; D016037:Single-Blind Method; D055815:Young Adult
chemical_list: D017553:Phosphorus Compounds; D016226:Phosphorus, Dietary; D010758:Phosphorus; C119467:lanthanum carbonate; D007811:Lanthanum